Patents by Inventor Joon-Ho SHEEN

Joon-Ho SHEEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITION COMPRISING ANTIGEN-PRESENTING CELL CO-EXPRESSING MHC AND TUMOR ANTIGEN, AND CANCER TREATMENT USING SAME
    Publication number: 20230338530
    Abstract: Provided are a vaccine composition for preventing or treating cancer, the vaccine composition comprising antigen-presenting cells, on the cell surface of which a complex of a major histocompatibility complex (MHC) and a tumor antigen is overexpressed, and cancer treatment using the same.
    Type: Application
    Filed: January 8, 2021
    Publication date: October 26, 2023
    Applicant: LG CHEM, LTD.
    Inventors: Joon Ho SHEEN, Joon Cheol KWON, Seunghae KIM
  • HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS
    Publication number: 20230002353
    Abstract: The present invention provides heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt, which are capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). This invention also provides pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The present invention is directed to MERTK inhibitory compounds with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to MERTK dysregulation.
    Type: Application
    Filed: December 30, 2020
    Publication date: January 5, 2023
    Inventors: Myeong-Seop KIM, Sumin KIM, Jin Kwan KIM, Hadong KIM, Ki Moon RYU, Seong Jin PARK, Taesun PARK, Joon-Ho SHEEN, Taeyoung YOON, Mi Yeon JANG
  • Heteroaryl compounds and their use as therapeutic drugs
    Patent number: 10947215
    Abstract: The present invention provides heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt, which are capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). This invention also provides pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The present invention is directed to MERTK inhibitory compounds with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to MERTK dysregulation.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: March 16, 2021
    Assignee: Dong-A Socio Holdings Co., Ltd.
    Inventors: Myeong-Seop Kim, Sumin Kim, Jin Kwan Kim, Hadong Kim, Ki Moon Ryu, Seong Jin Park, Taesun Park, Joon-Ho Sheen, Taeyoung Yoon, Mi Yeon Jang
  • HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS
    Publication number: 20190119252
    Abstract: The present invention provides heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt, which are capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). This invention also provides pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The present invention is directed to MERTK inhibitory compounds with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to MERTK dysregulation.
    Type: Application
    Filed: September 25, 2018
    Publication date: April 25, 2019
    Inventors: Myeong-Seop KIM, Sumin KIM, Jin Kwan KIM, Hadong KIM, Ki Moon RYU, Seong Jin PARK, Taesun PARK, Joon-Ho SHEEN, Taeyoung YOON, Mi Yeon JANG
  • Heteroaryl compounds and their use as therapeutic drugs
    Patent number: 10125118
    Abstract: The present invention provides heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt, which are capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). This invention also provides pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The present invention is directed to MERTK inhibitory compounds with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to MERTK dysregulation.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: November 13, 2018
    Assignee: Dong-A Socio Holdings Co., Ltd.
    Inventors: Myeong-Seop Kim, Sumin Kim, Jin Kwan Kim, Hadong Kim, Ki Moon Ryu, Seong Jin Park, Taesun Park, Joon-Ho Sheen, Taeyoung Yoon, Mi Yeon Jang
  • HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS
    Publication number: 20170355690
    Abstract: The present invention provides heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt, which are capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). This invention also provides pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The present invention is directed to MERTK inhibitory compounds with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to MERTK dysregulation.
    Type: Application
    Filed: August 31, 2016
    Publication date: December 14, 2017
    Inventors: Myeong-Seop KIM, Sumin KIM, Jin Kwan KIM, Hadong KIM, Ki Moon RYU, Seong Jin PARK, Taesun PARK, Joon-Ho SHEEN, Taeyoung YOON, Mi Yeon JANG
  • HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS
    Publication number: 20170066742
    Abstract: The present invention provides heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt, which are capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). This invention also provides pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The present invention is directed to MERTK inhibitory compounds with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to MERTK dysregulation.
    Type: Application
    Filed: August 31, 2016
    Publication date: March 9, 2017
    Inventors: Myeong-Seop KIM, Sumin KIM, Jin Kwan KIM, Hadong KIM, Ki Moon RYU, Seong Jin PARK, Taesun PARK, Joon-Ho SHEEN, Taeyoung YOON, Mi Yeon JANG